Preferences regarding Disclosure of Risk for Parkinson's Disease in a Population‐based Study

This pilot-study shows an open-minded view of participants towards disclosure of risk for future PD and a proactive attitude regarding dealing with one's risk.

Authors

Institutions

Publication Details

Journal
Movement Disorders Clinical Practice
Published
2024-11-18
DOI
https://doi.org/10.1002/mdc3.14264
Citations
5
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
1.85

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Preferences regarding Disclosure of Risk for Parkinson's Disease in a Population‐based Study

Alícia Garrido, Cristina Simonet, Atbin Djamshidian, Deborah McIntyre et al.
5 citations
Movement Disorders Clinical Practice
Parkinson's Disease Mechanisms and Treatments
1.85
article

Preferences regarding Disclosure of Risk for Parkinson's Disease in a Population‐based Study

Alícia Garrido, Cristina Simonet, Atbin Djamshidian, Deborah McIntyre, Kavita Rege, Heike Stockner, Claudia Trenkwalder, Daniel F. Pilco‐Janeta, Katarína Schwarzová, Laura Zamarian, Fernando Daniel Farfán, Alastair John Noyce, Iris Egner, Werner Poewe, Sebastian Schade, Corinne G.C. Horlings, Claire Pauly, Rejko Krueger, Kathrin Marini, Brit Mollenhauer, Klaus Seppi, Venkata Satagopam, Soumyabrata Ghosh, Philipp Mahlknecht, Christoph Theyer, Simon Leiter
article en
5 citations

Abstract

This pilot-study shows an open-minded view of participants towards disclosure of risk for future PD and a proactive attitude regarding dealing with one's risk.

Movement Disorders Clinical PracticeVol. 12(2)
Innsbruck Medical University (AT), Queen Mary University of London (GB), University of Luxembourg (LU), Universität Innsbruck (AT), Luxembourg Institute of Health (LU), Hospital Clínic de Barcelona (ES), Universitätsmedizin Göttingen (DE), Paracelsus Elena Klinik Kassel (DE), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Michael J. Fox Foundation for Parkinson's Research, AstraZeneca, Biogen, Teva Pharmaceutical Industries, Boston Scientific Corporation, Barts Charity, Leir Foundation, National Institute for Health and Care Research, European Commission, Deutsche Forschungsgemeinschaft, Austrian Science Fund, Oesterreichische Nationalbank, Novo Nordisk, H. Lundbeck A/S, Deutsche Parkinson Vereinigung, AOP Orphan, Economic and Social Research Council, UCB Pharma, EIT Health
Openalex Percentile: Top 13%
Parkinson's Disease Mechanisms and Treatments
1.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.